V. Barghout

发表

Costs of care for irritable bowel syndrome patients in a health maintenance organization

W. Whitehead, P. Stang, P. Jhingran, 2001 .

Burden of illness and healthcare resource use in United States patients with sporadic inclusion body myositis

G. Capkun, A. Callan, H. Tian, 2017, Muscle & nerve.

Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases.

J. Hay, M. Aapro, M. Botteman, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient-Reported Outcome Measures in Adult Patients Diagnosed with Epilepsy Being Treated with Perampanel

Shaloo Gupta, B. Moseley, C. Plauschinat, 2022, Patient related outcome measures.

Retrospective claims database analysis of elderly compared with nonelderly patients (pts) with newly diagnosed hepatocellular carcinoma (HCC).

A. Sanyal, É. Moyneur, V. Barghout, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between compliance, costs, hospitalizations for CML and GIST patients using imatinib mesylate

N. Mody-Patel, Denise Williams, R. Halpern, 2008 .

Costs of care for irritable bowel syndrome patients in a health maintenance organization

W. Whitehead, P. Stang, P. Jhingran, 2001, American Journal of Gastroenterology.

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐Induced neutropenia

Bree L. Dority, D. Perlman, F. Vekeman, 2009, Cancer.

Quality of life in managed care patients with irritable bowel syndrome.

G. Longstreth, C. Chiou, S. Wade, 2004, Managed care interface.

Irritable Bowel Syndrome, Health Care Use, and Costs: A U.S. Managed Care Perspective

G. Longstreth, C. Chiou, J. Ofman, 2003, American Journal of Gastroenterology.

A comparison of office-based physician visits for irritable bowel syndrome and for migraine and asthma.

C. Kozma, C. E. Reeder, F. Frech, 2002, Managed care interface.

IBS severity and health-related quality of life improve with age in women but not in men

D. Drossman, W. Whitehead, O. Palsson, 2003, American Journal of Gastroenterology.

Impairment in work productivity and health-related quality of life in patients with IBS.

B. Dean, D. Aguilar, J. Ofman, 2005, The American journal of managed care.

Population-based risk factors and resource utilization for HCC: US perspective

A. Sanyal, A. Poklepovic, É. Moyneur, 2010, Current medical research and opinion.

Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact

L. Chang, G. Locke, Lin Chang, 2005, Alimentary pharmacology & therapeutics.

The economic consequences of irritable bowel syndrome: a US employer perspective.

H. Birnbaum, R. Ben-Hamadi, J. Ofman, 2003, Archives of internal medicine.

Total costs of IBS: employer and managed care perspective.

S. Sullivan, B. Cash, V. Barghout, 2005, The American journal of managed care.

Direct medical costs of constipation in the United States.

B. Martin, A. Cerulli, V. Barghout, 2006, Managed care interface.

NATIONAL ESTIMATES OF OFFICE AND EMERGENCY ROOM CONSTIPATION-RELATED VISITS IN THE UNITED STATES: 754

B. Martin, V. Barghout, 2004 .

Costs and Utilization Associated with Imatinib Adherence in Patients with Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumors

Denise Williams, R. Halpern, V. Zarotsky, 2022 .

Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA

B. Tseng, F. Mastaglia, T. Lloyd, 2016, Journal of neuromuscular diseases.

Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective

Jonathan Karnon, T. Delea, J. Karnon, 2008, The European Journal of Health Economics.

Skeletal Muscle activity and Resource tool for sporadic Inclusion body Myositis (Smart-Sibm): Characterization of Resource Utilization and Financial Burden Experienced By Sibm Patients

B. Tseng, M. Price, V. Barghout, 2015 .

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

T. Delea, J. Karnon, Simu K. Thomas, 2007, Clinical breast cancer.

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib

M. Duh, F. Laliberté, M. Yenikomshian, 2019, The oncologist.

Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebo-control trial.

F. Saad, L. Abetz, V. Barghout, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases

Swu-Jane Lin, Mathew R. Smith, A. Lipton, 2008, Cancer.

Resource Utilization Associated with Irritable Bowel Syndrome in the United States: 1987–1997

P. Jhingran, R. Sandler, M. Halpern, 2002, Digestive Diseases and Sciences.

First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study

Jipan Xie, N. Li, E. Du, 2017, Current medical research and opinion.

Real-world impact of antiepileptic drug combinations with versus without perampanel on healthcare resource utilization in patients with epilepsy in the United States

E. Faught, M. Duh, F. Laliberté, 2021, Epilepsy & Behavior.

Isolation of less polar alkali-labile glycolipids of human brain by high-speed countercurrent chromatography

Ying Ma, S. Chatterjee, K. Matsuda, 1998 .

Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation

M. C. Reilly, V. Barghout, C. McBurney, 2005, Alimentary pharmacology & therapeutics.

Impairments in worker productivity and health-related quality of life among employees with irritable bowel syndrome: does bowel habit predominance make a difference?

B. Dean, D. Aguilar, J. Ofman, 2003, American Journal of Gastroenterology.

Impact of irritable bowel syndrome on worker productivity in an employed U.S. population

B. Dean, D. Aguilar, J. Ofman, 2003 .

PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK

T. Delea, J. Karnon, S. Johnston, 2005 .

Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer

Jipan Xie, E. Du, D. Tang, 2017, Expert opinion on pharmacotherapy.

Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome*

B. Martin, F. Frech, R. Ganguly, 2003, Current medical research and opinion.

The Economic Consequences of Irritable Bowel Syndrome

H. Birnbaum, R. Ben-Hamadi, J. Ofman, 2017 .

Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status.

F. Saad, Y. Hei, L. Abetz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real‐world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib

Yongling Xiao, C. Fuchs, M. Duh, 2018, Clinical colorectal cancer.

Budget impact of tegaserod on a managed care organization formulary.

Michael A. Bloom, B. Spiegel, I. Gralnek, 2005, The American journal of managed care.

Higher persistency with i.v. bisphosphonates in patients with bone metastasis.

H. Gothe, S. Mangiapane, V. Barghout, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States

E. Faught, B. Haider, M. Duh, 2017, Epilepsia.

PCN8 COMPARISON OF INFECTION-RELATED HOSPITALIZATION RISK AND ASSOCIATED COSTS AMONG PATIENTS RECEIVING SARGRAMOSTIM, FILGRASTIM, AND PEGFILGRASTIM FOR CHEMOTHERAPY-INDUCED NEUTROPENIA

Bree L. Dority, D. Perlman, M. Heaney, 2009 .

Dose reductions and delays in patients (pts) with renal cell carcinoma (RCC) treated with sorafenib (SR) or sunitinib (SU): Retrospective analysis of two large U.S. health care claims databases.

K. Flaherty, S. Keefe, É. Moyneur, 2010 .

Budget impact of perampanel as adjunctive treatment of uncontrolled partial-onset and primary generalized tonic–clonic seizures in the United States

G. Tremblay, W. Tsong, Zhixiao J. Wang, 2017, Epilepsy & Behavior.

Population-based risk factors and resource utilization for HCC: US perspective

A. Sanyal, A. Poklepovic, É. Moyneur, 2010, Current medical research and opinion.

PGI7 ECONOMIC OUTCOMES OF EMPLOYER BENEFICIARIES TREATED FOR IRRITABLE BOWEL SYNDROME (IBS)

H. Birnbaum, R. Ben-Hamadi, J. Ofman, 2002 .

Relationship between compliance with imatinib mesylate and medical costs for patients with CML and GIST

Denise Williams, R. Halpern, V. Barghout, 2007 .

Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia,

B. Tseng, F. Mastaglia, T. Lloyd, 2016 .